Richard Hoppe

Clinical Trials

• Recruiting Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
• Recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
• Recruiting Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies
• Not Recruiting Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
• Not Recruiting A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma
• Not Recruiting Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
• Recruiting Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
• Recruiting Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
• Recruiting Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
• Recruiting Combined Blood Stem Cell and Human Leukocyte Antigen (HLA) Haplotype Match Living Donor Kidney Transplantation
• Not Recruiting Rituximab in Treating Patients With Hodgkin's Lymphoma
• Not Recruiting An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
• Not Recruiting Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
• Not Recruiting A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
• Not Recruiting Allogeneic Transplantation From Related Haploidentical Donors in Older Patients With Indolent Hematologic Malignancies
• Not Recruiting Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
• Not Recruiting Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
• Not Recruiting Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A
• Not Recruiting Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
• Not Recruiting Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
• Not Recruiting Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
• Not Recruiting A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
• Not Recruiting Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
• Not Recruiting Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
• Not Recruiting Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
• Not Recruiting Phase II Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides
• Not Recruiting Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
• Not Recruiting Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma
• Recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
• Recruiting Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
• Recruiting Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma